Recent news on Abatacept

European Commission Grants Approval for ORENCIA(R) (abatacept) for ...  -  May 23, 2007
campus med,ORENCIA(R) (abatacept) for the treatment of rheumatoid arthritis (RA), a disease that may affect up to 4.5 million people in the European Union (1),(2).

FDA Approves Labeling Update For ORENCIA® (abatacept) To Inhibit ...  -  Apr 29, 2007
Medical News Today (press release),The labeling change is supported by two-year radiographic data from the Phase III AIM (Abatacept in Inadequate responders to MTX) trial, which met the

Bristol-Myers Squibb Breaks Ground on new Biologics Manufacturing ...  -  May 9, 2007
Pharmaceutical Processing,The facility will support increased production capacity for ORENCIA® (abatacept), the company's first internally discovered and developed biologic medicine,

Big bucks for BMS biologics base  -  May 3, 2007
DrugResearcher.com,The facility is being built to accommodate the production of BMS's popular rheumatoid arthritis medication Orencia (abatacept), first approved back in 2005

FDA Approves Labeling Update For ORENCIA To Inhibit Structural ...  -  Apr 30, 2007
Compliance Home,...(April 29, 2007)-- Myers Squibb Company announced that the US Food and Drug Administration (FDA) has approved an update to the ORENCIA (abatacept) product

Lupus gets new scrutiny, brighter outlook  -  Apr 28, 2007
Bradenton Herald,...trials of a Bristol-Myers Squibb drug called Abatacept, and trials in the United States of Hoffmann-La Roche's CellCept and Genentech's Rituximab.

Bristol-Myers Squibb relieved to see Plavix back on track  -  Apr 27, 2007
Pharma Times (subscription),...in the fourth quarter, while Orencia (abatacept) for rheumatoid arthritis brought in $41 million, up from $5 million in the same period last year.

FDA Approves Labeling Update for Orencia (abatacept) to Inhibit ...  -  Apr 25, 2007
PharmaLive.com (press release),The labeling change is supported by two-year radiographic data from the Phase III AIM (Abatacept in Inadequate responders to MTX) trial, which met the

New Hope For Lupus Sufferers  -  Apr 17, 2007
Hartford Courant,...but growing understanding of how it works has inspired new experiments, including international trials of a Bristol-Myers Squibb drug called Abatacept,

Lupus no longer fatal, but still needs attention  -  Apr 16, 2007
Inside Bay Area,...trials of a Bristol-Myers Squibb drug called Abatacept, and trials in the United States of Hoffmann-La Roche's CellCept and Genentech's Rituximab.

GlaxoSmithKline announces Altargo® receives positive opinion in ...  -  26 Mar 2007
WebWire (press release),London, UK - GlaxoSmithKline (GSK) today announced that its new, novel topical antibiotic ALTARGO® (retapamulin ointment, 1%) received a positive opinion

BMS extends large Lonza deal  -  Mar 13, 2007
In-PharmaTechnologist.com,Lonza has been asked by BMS to continue making the active pharmaceutical ingredient (API) for its rheumatoid arthritis biologic drug, Orencia (abatacept)

Lonza Rallies on Supply Deal with Bristol-Myers  -  Mar 12, 2007
Reuters.uk,The extension of the deal, for manufacturing the biologic agent abatacept at Portsmouth, New Hampshire, will give Bristol-Myers more production capacity for

Meeting Highlights From The Committee For Medicinal Products For ...  -  Mar 23, 2007
Medical News Today (press release),Orencia (abatacept), from Bristol-Myers Squibb Pharma EEIG, intended for the treatment of moderately to severely active rheumatoid arthritis.

New biologics facility for BMS  -  Feb 20, 2007
In-PharmaTechnologist.com,The new site is intended to support increased production capacity of biologic compounds such as the company's Orencia (abatacept) for rheumatoid arthritis,

Bristol-Myers Squibb Completes Land Acquisition for New Biologics ...  -  Feb 19, 2007
Drug Newswire (press release),...available biologic compounds, such as ORENCIA(R) (abatacept), and help meet future production needs of biologic compounds currently in development,

Bristol-Myers Squibb Completes Land Acquisition for New Biologics ...  -  Feb 16, 2007
Yahoo! News (press release)...manufacturing facility is expected to support increased production capacity for commercially available biologic compounds, such as ORENCIA® (abatacept),

Arthritis Clinical Trial Results Revealed  -  Jan 2, 2007
Journal of American Medical Association (subscription),Another trial assessed the potential of combination therapy of methotrexate and infliximab or abatacept for patients with rheumatoid arthritis.

Companies Rely on RCT Protein Expression Technology to Make ...  -  26 Dec 2006
PharmaLive.com (press release),Three currently available therapeutics that are produced using the bgh-polyA signal include Bristol-Myers Squibb's ORENCIA(R) (abatacept), a receptor fusion

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional